Biopartners goes biobetter as sustained release hGH shows Phase III promise
This article was originally published in Scrip
Executive Summary
Biopartners, a Swiss firm focused on biogenerics, and LG Life Sciences (LGLS; South Korea) have presented positive Phase III results of 24 months efficacy and safety in children with growth hormone deficiency (GHD) for LB03002, a once-a-week, sustained release recombinant human growth hormone (hGH), at the annual meeting of the European Society for Paediatric Endocrinology (ESPE 2011) in Glasgow, Scotland.